## Hiroyuki Ito

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7652079/publications.pdf

Version: 2024-02-01

361413 223800 2,639 109 20 46 citations h-index g-index papers 114 114 114 2469 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Complex Segmentectomy for Hypermetabolic Clinical Stage IA Non-Small Cell Lung Cancer. Annals of Thoracic Surgery, 2022, 113, 1317-1324.	1.3	2
2	Adjuvant Chemotherapy for High-risk Pathologic Stage I Non-Small Cell Lung Cancer. Annals of Thoracic Surgery, 2022, 113, 1608-1616.	1.3	25
3	Impact of the first surge of the coronavirus disease pandemic on general thoracic surgery practices in Kanagawa: a questionnaire survey by the Kanagawa General Thoracic Surgical Study Group. General Thoracic and Cardiovascular Surgery, 2022, 70, 265-272.	0.9	2
4	Oncological outcome of segmentectomy for early-stage non-small-cell lung cancer with invasive characteristics: a multicentre study. European Journal of Cardio-thoracic Surgery, 2022, 62, .	1.4	8
5	The impact of epidermal growth factor receptor mutation status on adjuvant chemotherapy for patients with high-risk stage I lung adenocarcinoma. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 1306-1315.e4.	0.8	14
6	Circulating Tumor Cells and the Non-Touch Isolation Technique in Surgery for Non-Small-Cell Lung Cancer. Cancers, 2022, 14, 1448.	3.7	4
7	The prognostic impact of the ground-glass opacity component in nearly pure-solid stage IA non-small-cell lung cancer. European Journal of Cardio-thoracic Surgery, 2022, 62, .	1.4	10
8	Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet, The, 2022, 399, 1607-1617.	13.7	537
9	A Multicenter Study of Complex Segmentectomy versus Wedge Resection in Clinical Stage 0-IA Non-Small Cell Lung Cancer. Clinical Lung Cancer, 2022, , .	2.6	3
10	Limited resection for stage IA radiologically invasive lung cancer: a real-world nationwide database study. European Journal of Cardio-thoracic Surgery, 2022, 62, .	1.4	14
11	Salvage Surgery for Non-Small Cell Lung Cancer After Definitive Radiotherapy. Annals of Thoracic Surgery, 2021, 112, 862-873.	1.3	16
12	Comparison of cancer control between segmentectomy and wedge resection in patients with clinical stage IA non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, 1244-1252.e1.	0.8	27
13	Prognostic impact of a ground-glass opacity component in clinical stage IA non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2021, 161, 1469-1480.	0.8	83
14	Long-term survival outcome after lobectomy in patients with clinical T1 N0 lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2021, 161, 281-290.	0.8	35
15	Clinical Impacts of EGFR Mutation Status: Analysis of 5780 Surgically Resected Lung Cancer Cases. Annals of Thoracic Surgery, 2021, 111, 269-276.	1.3	66
16	Recent advances and future perspectives in adjuvant and neoadjuvant immunotherapies for lung cancer. Japanese Journal of Clinical Oncology, 2021, 51, 28-36.	1.3	8
17	Oncologic Outcomes of Complex Segmentectomy: A Multicenter Propensity Score-Matched Analysis. Annals of Thoracic Surgery, 2021, 111, 1044-1051.	1.3	12
18	Long-Term Outcomes After Sublobar Resection Versus Lobectomy in Patients With Clinical Stage IA Lung Adenocarcinoma Meeting the Node-Negative Criteria Defined by High-Resolution Computed Tomography and [18F]-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography. Clinical Lung Cancer, 2021, 22, e431-e437.	2.6	4

#	Article	IF	CITATIONS
19	Tissue surface area and tumor cell count affect the success rate of the Oncomine Dx Target Test in the analysis of biopsy tissue samples. Thoracic Cancer, 2021, 12, 194-200.	1.9	12
20	Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment. Lung Cancer, 2021, 153, 108-116.	2.0	28
21	Clinical features and outcomes of patients with stage I multiple primary lung cancers. Cancer Science, 2021, 112, 1924-1935.	3.9	16
22	Comprehensive molecular analysis of genomic profiles and PD-L1 expression in lung adenocarcinoma with a high-grade fetal adenocarcinoma component. Translational Lung Cancer Research, 2021, 10, 1292-1304.	2.8	7
23	Prediction of Unexpected N2 Disease Associated With Clinical T1-2N0-1M0 Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2021, 22, 120-126.e3.	2.6	7
24	Detection of EGFR mutation of pulmonary adenocarcinoma in sputum using droplet digital PCR. BMC Pulmonary Medicine, 2021, 21, 100.	2.0	9
25	Preoperative nivolumab to evaluate pathological response in patients with stage I non-small cell lung cancer: a study protocol of phase II trial (POTENTIAL). BMJ Open, 2021, 11, e043234.	1.9	3
26	Usefulness of monitoring intrapleural pressure with digital chest drainage system for the management of air leakage after lung resection. Interactive Cardiovascular and Thoracic Surgery, 2021, 33, 580-587.	1.1	2
27	Identification of High-Risk of Recurrence in Clinical Stage I Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 622742.	2.8	4
28	Anatomical location and number of metastatic lymph nodes for prognosis of non-small cell lung cancer. Journal of Thoracic Disease, 2021, 13, 4083-4093.	1.4	3
29	Feasibility of application of an absorbable topical collagen hemostat sheet (INTEGRAN®) for prevention of postoperative recurrence of pneumothorax in youths. Journal of Thoracic Disease, 2021, 13, 3979-3987.	1.4	0
30	Risk of death due to other causes is lower among octogenarians with non-small cell lung cancer after wedge resection than lobectomy/segmentectomy. Japanese Journal of Clinical Oncology, 2021, 51, 1561-1569.	1.3	5
31	Systematic Versus Lobe-Specific Mediastinal Lymphadenectomy for Hypermetabolic Lung Cancer. Annals of Surgical Oncology, 2021, 28, 7162-7171.	1.5	14
32	The impact of pathological lymph node metastasis with lymphatic invasion on the survival of patients with clinically node-negative non-small cell lung cancer: A multicenter study. Lung Cancer, 2021, 158, 9-14.	2.0	12
33	Surgical challenges in multimodal treatment of N2-stage IIIA non-small cell lung cancer. Japanese Journal of Clinical Oncology, 2021, 51, 333-344.	1.3	6
34	Impact of the initial site of recurrence on prognosis after curative surgery for primary lung cancer. European Journal of Cardio-thoracic Surgery, 2021, , .	1.4	4
35	Effect of epidermal growth factor receptor gene mutation on the prognosis of pathological stage II–IIIA (8th edition TNM classification) primary lung cancer after curative surgery. Lung Cancer, 2021, 162, 128-134.	2.0	5
36	Appropriate Extent of Lymphadenectomy in Segmentectomy: A Multicenter Study. Japanese Journal of Clinical Oncology, 2021, 51, 451-458.	1.3	5

#	Article	IF	Citations
37	A prophylaxis study of acute exacerbation of interstitial pneumonia after lung cancer surgery. Japanese Journal of Clinical Oncology, 2020, 50, 198-205.	1.3	11
38	High gamma-glutamyl hydrolase and low folylpolyglutamate synthetase expression as prognostic biomarkers in patients with locally advanced gastric cancer who were administrated postoperative adjuvant chemotherapy with S-1. Journal of Cancer Research and Clinical Oncology, 2020, 146, 75-86.	2.5	8
39	Impact of the ESM-1 Gene Expression on Outcomes in Stage II/III Gastric Cancer Patients Who Received Adjuvant S-1 Chemotherapy. In Vivo, 2020, 34, 461-467.	1.3	12
40	Impact of the preoperative body mass index on the postoperative outcomes in patients with completely resected non-small cell lung cancer: A retrospective analysis of 16,503 cases in a Japanese Lung Cancer Registry Study. Lung Cancer, 2020, 149, 120-129.	2.0	10
41	Clinical Significance of Tumour CD44v and MIST1 Expression in Patients With Non-small-cell Lung Cancer. Anticancer Research, 2020, 40, 6407-6416.	1.1	1
42	Solid Tumor Size of 2 cm Divides Outcomes of Patients With Mixed Ground Glass Opacity Lung Tumors. Annals of Thoracic Surgery, 2020, 109, 1530-1536.	1.3	15
43	Prognosis of segmentectomy and lobectomy for radiologically aggressive small-sized lung cancer. European Journal of Cardio-thoracic Surgery, 2020, 58, 1245-1253.	1.4	19
44	Impact of the micropapillary component on the timing of recurrence in patients with resected lung adenocarcinoma. European Journal of Cardio-thoracic Surgery, 2020, 58, 1010-1018.	1.4	25
45	A Case of Unresectable Papillary Thyroid Carcinoma Treated with Lenvatinib as Neoadjuvant Chemotherapy. Case Reports in Endocrinology, 2020, 2020, 1-4.	0.4	12
46	Wedge resection as an alternative treatment for octogenarian and older patients with early-stage non–small-cell lung cancer. Japanese Journal of Clinical Oncology, 2020, 50, 1051-1057.	1.3	12
47	Positive EGFR mutation status is a risk of recurrence in pN0–1 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysis. Lung Cancer, 2020, 141, 107-113.	2.0	33
48	Impact of Postoperative Complications on Recurrence in Patients With Stage II/III Gastric Cancer Who Received Adjuvant Chemotherapy With S-1. Anticancer Research, 2020, 40, 1683-1690.	1.1	3
49	Risk factors for progressive sarcopenia 6 months after complete resection of lung cancer: what can thoracic surgeons do against sarcopenia?. Journal of Thoracic Disease, 2020, 12, 307-318.	1.4	1
50	Effect of epidermal growth factor receptor mutation on early-stage non-small cell lung cancer according to the 8th TNM classification. Lung Cancer, 2020, 145, 111-118.	2.0	8
51	Efficacy of Platinum-Based Adjuvant Chemotherapy on Prognosis of Pathological Stage II/III Lung Adenocarcinoma based on EGFR Mutation Status: A Propensity Score Matching Analysis. Molecular Diagnosis and Therapy, 2019, 23, 657-665.	3.8	7
52	Bronchovascular sleeve resection of the right middle lobe in N1 lung cancer. AME Case Reports, 2019, 3, 5-5.	0.6	1
53	Which Window Setting Is Best for Estimating Pathologic Invasive Size and Invasiveness?. Annals of Thoracic Surgery, 2019, 108, 384-391.	1.3	2
54	Prognostic significance of blood and lymphatic vessel invasion in pathological stage IA lung adenocarcinoma in the 8th edition of the TNM classification. Lung Cancer, 2019, 137, 144-148.	2.0	17

#	Article	IF	Citations
55	High-Risk Factors for Recurrence of Stage I Lung Adenocarcinoma: Follow-up Data From JCOG0201. Annals of Thoracic Surgery, 2019, 108, 1484-1490.	1.3	26
56	Clinical Significance of <i>PRKCI</i> Gene Expression in Cancerous Tissue in Patients With Gastric Cancer. Anticancer Research, 2019, 39, 5715-5720.	1.1	11
57	Two cases of lung neuroendocrine carcinoma with carcinoid morphology. Diagnostic Pathology, 2019, 14, 104.	2.0	15
58	Effect of progressive sarcopenia during postoperative 6 months on long-term prognosis of completely resected lung cancer. Journal of Thoracic Disease, 2019, 11, 3411-3420.	1.4	7
59	Should Pathologically Noninvasive Lung Adenocarcinoma Larger Than 3 cm Be Classified as T1a?. Annals of Thoracic Surgery, 2019, 108, 1678-1684.	1.3	7
60	CD271 is a negative prognostic factor and essential for cell proliferation in lung squamous cell carcinoma. Laboratory Investigation, 2019, 99, 1349-1362.	3.7	11
61	Postoperative changes of the free pericardial fat pad for bronchial stump coverage. Journal of Thoracic Disease, 2019, 11, 5228-5236.	1.4	7
62	Clinical Significance of KIAA1199 as a Novel Target for Gastric Cancer Drug Therapy. Anticancer Research, 2019, 39, 6567-6573.	1.1	10
63	Demographics, Safety and Quality, and Prognostic Information in Both the Seventh and Eighth Editions of the TNM Classification in 18,973 Surgical Cases of the Japanese Joint Committee of Lung Cancer Registry Database in 2010. Journal of Thoracic Oncology, 2019, 14, 212-222.	1.1	136
64	Adjuvant chemotherapy for pathological stage I non-small cell lung cancer with high-risk factors for recurrence: A multicenter study Journal of Clinical Oncology, 2019, 37, 8500-8500.	1.6	5
65	Oncologic outcomes of segmentectomy versus lobectomy for radiologically aggressive small-sized lung cancer Journal of Clinical Oncology, 2019, 37, 8525-8525.	1.6	0
66	High co-expression of IL-34 and M-CSF correlates with tumor progression and poor survival in lung cancers. Scientific Reports, 2018, 8, 418.	3.3	88
67	A surgical case of synchronous multiple thymoma of multicentric origin. The Journal of the Japanese Association for Chest Surgery, 2018, 32, 78-83.	0.0	1
68	A proposal for a comprehensive risk scoring system for predicting postoperative complications in octogenarian patients with medically operable lung cancer: JACS1303. European Journal of Cardio-thoracic Surgery, 2018, 53, 835-841.	1.4	40
69	Phase II study of nedaplatin and irinotecan as adjuvant chemotherapy for completely resected non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2018, 81, 81-87.	2.3	6
70	What factors determine the survival of patients with an acute exacerbation of interstitial lung disease after lung cancer resection?. Surgery Today, 2018, 48, 404-415.	1.5	8
71	Thoracoscopic right S6 sleeve segmentectomy for squamous-cell carcinoma arising from the B6 central bronchus. Journal of Thoracic Disease, 2018, 10, 1077-1080.	1.4	5
72	Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery. BMC Cancer, 2018, 18, 959.	2.6	21

#	Article	IF	Citations
73	Pulmonary adenocarcinoma with high-grade fetal adenocarcinoma component has a poor prognosis, comparable to that of micropapillary adenocarcinoma. Modern Pathology, 2018, 31, 1404-1417.	5.5	22
74	S <sup>1+2+6</sup> segmentectomy for a case of lung cancer arising in a displaced anomalous bronchus. The Journal of the Japanese Association for Chest Surgery, 2018, 32, 847-852.	0.0	1
75	Long-term outcomes after sublobar resection for clinical stage IA lung adenocarcinoma meeting node-negative criteria defined by HRCT and FDG-PET/CT Journal of Clinical Oncology, 2018, 36, 8554-8554.	1.6	0
76	A surgical case of non-small cell lung cancer in a patient with lymph node recurrence after carbon ion radiotherapy. The Journal of the Japanese Association for Chest Surgery, 2018, 32, 641-646.	0.0	0
77	A prospective, multi-institutional phase II study of induction chemoradiotherapy followed by surgery in patients with non-small cell lung cancer involving the chest wall (CJLSG0801). Lung Cancer, 2017, 104, 79-84.	2.0	22
78	Does the histologic predominance of pathological stage IA lung adenocarcinoma influence the extent of resection?. General Thoracic and Cardiovascular Surgery, 2017, 65, 512-518.	0.9	19
79	Detection of tumor spread through airspaces by airway secretion cytology from resected lung cancer specimens. Pathology International, 2017, 67, 487-494.	1.3	21
80	Neoadjuvant and adjuvant therapy for Stage III non-small cell lung cancer. Japanese Journal of Clinical Oncology, 2017, 47, 1112-1118.	1.3	57
81	A case of right lower lobectomy with abnormal mediastinal A <sup>7</sup> a+ <sup>8</sup> b branching. The Journal of the Japanese Association for Chest Surgery, 2017, 31, 684-688.	0.0	1
82	V-082SUPERIOR SULCUS TUMOUR RECURRED AFTER DEFINITIVE CHEMORADIOTHERAPY SUCCESSFULLY RESECTED WITH TRANSMANUBRIAL AND PAULSON APPROACH. Interactive Cardiovascular and Thoracic Surgery, 2017, 25, .	1.1	0
83	A Case of Metastasis to the Anterior Mediastinum from Carcinoma Showing Thymus-like Differentiation (CASTLE). Japanese Journal of Lung Cancer, 2017, 57, 292-298.	0.1	0
84	Second predominant subtype predicts outcomes of intermediate-malignant invasive lung adenocarcinoma. European Journal of Cardio-thoracic Surgery, 2016, 51, ezw318.	1.4	10
85	Epidermal Growth Factor Receptor Mutations and Prognosis in Pathologic N1-N2 Pulmonary Adenocarcinoma. Annals of Thoracic Surgery, 2016, 102, 1821-1828.	1.3	14
86	Prognostic significance of vascular invasion in intermediate-grade subtype of lung adenocarcinoma. Japanese Journal of Clinical Oncology, 2016, 46, 1015-1021.	1.3	5
87	Feasibility and efficacy of salvage lung resection after definitive chemoradiation therapy for Stage III non-small-cell lung cancer. Interactive Cardiovascular and Thoracic Surgery, 2016, 23, 895-901.	1.1	30
88	Suspected Aerogenous Lung Metastases From Nasopharyngeal Cancer. Annals of Thoracic Surgery, 2016, 101, e157-e159.	1.3	1
89	Relationship between phosphorylation of sperm-specific antigen and prognosis of lung adenocarcinoma. Journal of Proteomics, 2016, 139, 60-66.	2.4	13
90	Prediction of lung tumor palpability using high-resolution computed tomography. Asian Cardiovascular and Thoracic Annals, 2016, 24, 23-29.	0.5	0

#	Article	IF	CITATIONS
91	Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria. Surgery Today, 2016, 46, 668-685.	1.5	541
92	Negative prognostic influence of micropapillary pattern in stage IA lung adenocarcinoma. European Journal of Cardio-thoracic Surgery, 2016, 49, 293-299.	1.4	40
93	A Case of Lung Pleomorphic Carcinoma with an EML4-ALK Mutation Presenting as Ground-glass Attenuation Around the Tumor. Japanese Journal of Lung Cancer, 2016, 56, 98-102.	0.1	1
94	A prospective, multi-institutional phase II study of induction chemoradiotherapy followed by surgery in patients with non-small cell lung cancer involving the chest wall (CJLSG0801) Journal of Clinical Oncology, 2016, 34, 8525-8525.	1.6	0
95	Analysis of patients (pts) with pathological (p-) stage I (T1 > 2 cm) non small cell lung cancer (NSCLC) who were excluded from clinical trial of adjuvant chemotherapy Journal of Clinical Oncology, 2016, 34, e20018-e20018.	1.6	0
96	Plexiform schwannoma involving the trachea and recurrent laryngeal nerve: a case report. Surgical Case Reports, $2015, 1, 67$ .	0.6	4
97	Outcomes of Lobectomy in  Active' Octogenarians with Clinical Stage I Non-Small-Cell Lung Cancer. Annals of Thoracic and Cardiovascular Surgery, 2015, 21, 24-30.	0.8	7
98	Relation Between Thin-Section Computed Tomography and Clinical Findings of Mucinous Adenocarcinoma. Annals of Thoracic Surgery, 2015, 99, 975-981.	1.3	53
99	Diagnosis of metachronous multiple lung adenocarcinoma at the cut-end by epidermal growth factor receptor mutation status discordance 4Ayears after sublobar resection for adenocarcinoma in situ: report of a case. Surgery Today, 2015, 45, 1330-1334.	1.5	5
100	Reply. Annals of Thoracic Surgery, 2015, 100, 1507.	1.3	3
101	Thin-section CT and Clinical Findings of Adenosquamous Lung Carcinoma and Lung Pleomorphic Carcinoma. Japanese Journal of Lung Cancer, 2015, 55, 1045-1053.	0.1	3
102	Prophylaxis for acute exacerbation of interstitial pneumonia after lung resection. Asian Cardiovascular and Thoracic Annals, 2014, 22, 948-954.	0.5	18
103	Surgical Treatment for Synchronous Primary LungÂAdenocarcinomas. Annals of Thoracic Surgery, 2014, 98, 1983-1988.	1.3	46
104	Comparison between CT tumor size and pathological tumor size in frozen section examinations of lung adenocarcinoma. Lung Cancer, 2014, 85, 40-46.	2.0	33
105	Trimodality Therapy for Lung Cancer With Chest Wall Invasion: Initial Results of a Phase II Study. Annals of Thoracic Surgery, 2014, 98, 1184-1191.	1.3	22
106	Subpleural Honeycombing on High Resolution Computed Tomography is Risk Factor for Fatal Pneumonitis. Annals of Thoracic Surgery, 2011, 91, 874-878.	1.3	12
107	Surgical outcomes and reevaluation of treatment strategies for thymomas. Oncology Letters, 2010, 1, 761-764.	1.8	0
108	Expression of vascular endothelial growth factor and basic fibroblast growth factor in small adenocarcinomas. Oncology Reports, 2002, 9, 119-23.	2.6	17

#	Article	IF	CITATIONS
109	Successful operation for lung cancer patient with idiopathic thrombocytopenic purpura by preoperative high-dose intravenous gammaglobulin. A case report The Journal of the Japanese Association for Chest Surgery, 2000, 14, 850-853.	0.0	0